Company intelligence / Profile preview
Clinuvel Pharmaceuticals
- Ownership
- Public · CUV
- Employees
- ~16
- Development stage
- Commercial
Overview
Clinuvel’s lead product SCENESSE® (afamelanotide) is approved in the US, Europe, Israel, and Australia for preventing phototoxicity in adult EPP patients. The company has completed enrollment of a global Phase III trial evaluating afamelanotide in vitiligo. Additional programs are advancing through clinical development targeting acute CNS disorders and other unmet needs with melanocortin-based therapies.
- Therapeutic areas
- EndocrinologyRare DiseasesDermatologyCardiovascularNeurology
- Modalities
- Peptidesmelanocortin analoguesACTH
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $261.1M
- Total revenue
- $64.7M
- Enterprise value
- $89.1M
Beyond the preview
Go deeper on Clinuvel Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clinuvel Pharmaceuticals.